1,4-二氯二氮杂萘-6-甲腈 | 178308-61-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,4-二氯二氮杂萘-6-甲腈
• 中文别名: 1,4-二氯酞嗪-6-甲腈
• 英文名称: 1,4-dichlorophthalazine-6-carbonitrile
• 英文别名: 6-cyano-1,4-dichlorophthalazine；1,4-dichloro-6-cyanophthalazine
• CAS: 178308-61-7
• 化学式: C₉H₃Cl₂N₃
• 分子量: 224.049
• InChiKey: FRJDQOMCKHDEJQ-UHFFFAOYSA-N

物化性质

• 沸点：
  482.9±40.0 °C(Predicted)
• 密度：
  1.57

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  14
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-氯-4-甲氧基苄胺 、 1,4-二氯二氮杂萘-6-甲腈 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 生成 1-chloro-4-(3-chloro-4-methoxybenzyl)amino-6-cyanophthalazine
  参考文献：
  名称：

  Remedy for erection failure comprising fused pyridazine compound

  摘要：

  该发明提供了一种治疗勃起功能障碍的药物。其活性成分是由以下式(I)表示的融合吡啶嗪化合物或其药理学上可接受的盐：（其中环C代表具有杂原子的5或6元环；n为1到4的整数；R1代表氢、卤素、氰基等；A代表氢、卤素、可选择取代的氨基等；X代表由式—N═表示的基团等；Y代表式—CO—、可选择取代的氨基等）。

  公开号：

  US06288064B1
• 作为产物：
  描述：

  trimellitic acid amide-imide 在 N-甲基吡咯烷酮 、 氯化亚砜 、 一水合肼 、 三氯氧磷 作用下， 反应 0.5h， 生成 1,4-二氯二氮杂萘-6-甲腈
  参考文献：
  名称：

  4-Benzylamino-1-chloro-6-substituted Phthalazines:  Synthesis and Inhibitory Activity toward Phosphodiesterase 5

  摘要：

  We synthesized various 4-benzylamino-1-chloro-6-substituted phthalazines (15) and 4-benzylamino-1-chloro-7-substituted phthalazines (16) and evaluated their inhibitory activity toward phosphodiesterase 5 (PDE5) purified from porcine platelets. The PDE5-inhibitory activities of 15 were greater than those of the isomers (16). The preferred substituent at the 4-position of phthalazine was a (3-chloro-4-methoxybenzyl)amino group, and those at the B-position were cyano, nitro, and trifluoromethyl groups. Compounds 15a (IC50 = 4.8 nM), 15f (3.5 nM), and 15i (5.3 nM) were more potent inhibitors than E4021 (8.6 nM). Compounds 15a and 15f also showed vasorelaxant activity in isolated porcine coronary arteries precontracted with prostaglandin F-2 alpha (10(-5) M). The EC50 values for vasorelaxant action of 15a, 15f, and E4021 were 150, 160, and 980 nM, respectively. These results show that novel PDE5 inhibitors possessing a potent vasorelaxant effect may exist among phthalazine derivatives.

  DOI：

  10.1021/jm970815r

文献信息

• Phthalazine derivatives and remedies for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US06498159B1

  公开（公告）日：2002-12-24

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: wherein R1 and R2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R1 is a chlorine atom, R2 is a methoxy group and Y is a 5- or 6-membered amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种邻苯二氮杂环化合物，作为下式所代表的勃起功能障碍的治疗剂，其药理学上可接受的盐或水合物： 其中R1和R2相同或不同，分别代表卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X代表氰基、硝基、卤素原子、可能被取代的羟基亚胺基团或可能被取代的杂芳基团；Y代表杂芳基团、可能被取代的芳基团、可能被取代的炔基团、烯基团、烷基团、可选择地取代的饱和或不饱和的4-至8-成员氨基环，且环状胺化合物是单环化合物、双环化合物或螺环化合物；l为1到3的整数；但在l为1或2的情况下，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基团，Y为取代羟基的5-或6-成员氨基环的情况除外。
• Phthalazine compounds, compositions and methods of use
  申请人：Austin Richard J.

  公开号：US20090048259A1

  公开（公告）日：2009-02-19

  The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.

  本发明一般涉及在式I中表示的化合物，包括它们的药物组合物以及治疗癌症等疾病或疾病的方法。
• Fused pyridazine compounds
  申请人：Eisai Co., Ltd.

  公开号：US05849741A1

  公开（公告）日：1998-12-15

  A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma. ##STR1##

  以下是一种融合吡啶并嘧啶化合物，其化学式如下（I），或其药理学上可接受的盐，具有对环磷酸鸟苷磷酸二酯酶（以下简称“cGMP-PDE”）的抑制活性。这些化合物可用作预防和治疗剂，用于对于cGMP-PDE抑制活性有效的疾病，例如缺血性心脏病，如心绞痛，心肌梗死和慢性和急性心衰，肺动脉高压，动脉硬化和支气管哮喘。##STR1##
• Phthalazine compounds and therapeutic agents for erectile dysfunction
  申请人：Eisai Co., Ltd.

  公开号：US20030105074A1

  公开（公告）日：2003-06-05

  The present invention provides a phthalazine compound as a therapeutic agent for erectile dysfunction represented by the following formula, a pharmacologically acceptable salt thereof or a hydrate thereof: 1 wherein R 1 and R 2 are the same as or different from each other and represent a halogen atom, a C1 to C4 alkyl group which may be substituted with a halogen atom, a C1 to C4 alkoxy group which may be substituted with a halogen atom or a cyano group; X represents a cyano group, a nitro group, a halogen atom, a hydroxyimino group which may be substituted or a heteroaryl group which may be substituted; Y represents a heteroaryl group, an aryl group which may be substituted, an alkynyl group which may substituted, an alkenyl group, an alkyl group, an optionally substituted saturated or unsaturated 4- to 8-membered amine ring, and the cyclic amine compound is a monocyclic compound, bicyclic compound or a spiro compound; l is an integer of 1 to 3; provided that the case where l is 1 or 2, X is a cyano group, a nitro group or a chlorine atom, R 1 is a chlorine atom, R 2 is a methoxy group and Y is a 5- or 6-memberred amine ring substituted with a hydroxyl group is excluded.

  本发明提供了一种治疗勃起功能障碍的邻苯二氮杂环化合物，其化学式如下，其药理学上可接受的盐或水合物：1其中，R1和R2相同或不同，表示卤素原子、可能被卤素原子取代的C1到C4烷基、可能被卤素原子取代的C1到C4烷氧基或氰基；X表示氰基、硝基、卤素原子、可能被取代的羟肟基或可能被取代的杂环基；Y表示杂环基、可能被取代的芳基、可能被取代的炔基、烯基、烷基、可选取代的饱和或不饱和4-至8环胺环，所述的环胺化合物是单环化合物、双环化合物或螺环化合物；l是1到3的整数；但当l为1或2时，X为氰基、硝基或氯原子，R1为氯原子，R2为甲氧基，Y为取代有羟基的5-或6环胺环时，不在此范围内。
• FUSED PYRIDAZINE COMPOUND
  申请人：Eisai Co., Ltd.

  公开号：EP0722936A1

  公开（公告）日：1996-07-24

  A fused pyridazine compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof which exhibits an inhibitory activity against cyclic GMP phosphodiesterase (hereinafter referred to as "cGMP-PDE"). The compounds are useful as preventive and therapeutic agents for diseases for which a cGMP-PDE inhibiting action is efficacious, for example, ischemic heart diseases such as angina pectoris, myocardial infarct and chronic and acute cardiac failure, pulmonary hypertension, arteriosclerosis and bronchial asthma.

  由以下通式（I）代表的融合哒嗪化合物或其药理学上可接受的盐，对环 GMP 磷酸二酯酶（以下简称 "cGMP-PDE"）具有抑制活性。 这些化合物可作为 cGMP-PDE 抑制作用有效的疾病的预防和治疗药物，例如缺血性心脏病，如心绞痛、心肌梗塞、慢性和急性心力衰竭、肺动脉高压、动脉硬化和支气管哮喘。